{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:24:31Z","timestamp":1785281071039,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejim.2025.06.001","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T07:06:41Z","timestamp":1749884801000},"page":"106372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Identification of risk factors for permanent visual loss in patients with giant cell arteritis"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-1293","authenticated-orcid":false,"given":"Roser","family":"Solans-Laqu\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"de Escalante-Yanguela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0578-7474","authenticated-orcid":false,"given":"Eva","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"Fraile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2673-2034","authenticated-orcid":false,"given":"Ferran","family":"Mart\u00ednez-Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Caminal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Monteagudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"P\u00e9rez-Conesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Gracia-Tello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Abdilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3179-597X","authenticated-orcid":false,"given":"Sergio","family":"Prieto-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleida","family":"Mart\u00ednez-Zapico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"de Miguel-Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6612-221X","authenticated-orcid":false,"given":"Jaume","family":"Mestre-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2025.06.001_bib0001","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.1780330810","article-title":"The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis","volume":"33","author":"Hunder","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2025.06.001_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2025.06.001_bib0003","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/01.md.0000180042.42156.d1","article-title":"Llorca Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients","volume":"84","author":"Gonzalez-Gay","year":"2005","journal-title":"Medicine"},{"key":"10.1016\/j.ejim.2025.06.001_bib0004","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMcp1214825","article-title":"Giant-cell arteritis and polymyalgia rheumatica","volume":"371","author":"Weyand","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.06.001_bib0005","first-page":"506","article-title":"The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease","volume":"56","author":"Dejaco","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ejim.2025.06.001_bib0006","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z","article-title":"Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment","volume":"41","author":"Gonz\u00e1lez-Gay","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2025.06.001_bib0007","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/rheumatology\/ken465","article-title":"Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis","volume":"48","author":"Salvarani","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ejim.2025.06.001_bib0008","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nrrheum.2017.98","article-title":"Visual loss and other cranial ischaemic complications in giant cell arteritis","volume":"13","author":"Soriano","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ejim.2025.06.001_bib0009","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1093\/rheumatology\/keaa058","article-title":"Risk factors for severe cranial ischaemic complications in giant cell arteritis","volume":"59","author":"Hocevar","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejim.2025.06.001_bib0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/rheumatology\/36.2.251","article-title":"Clinical features in patients with permanent visual loss due to biopsy-proven Giant Cell Arteritis","volume":"36","author":"Font","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.ejim.2025.06.001_bib0011","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00005792-200009000-00001","article-title":"Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients","volume":"79","author":"Gonzalez-Gay","year":"2000","journal-title":"Medicine"},{"key":"10.1016\/j.ejim.2025.06.001_bib0012","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.ophtha.2016.05.008","article-title":"Evaluating the incidence of arteritic ischemic optic neuropathy and other causes of vision loss from giant cell arteritis","volume":"123","author":"Chen","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejim.2025.06.001_bib0013","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3899\/jrheum.140188","article-title":"Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort","volume":"42","author":"Singh","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2025.06.001_bib0014","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0","article-title":"Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis","volume":"41","author":"Cid","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2025.06.001_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3899\/jrheum.151135","article-title":"Risk factors for permanent visual loss in biopsy-proven giant cell arteritis. A study of 339 patients","volume":"43","author":"Liozon","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2025.06.001_bib0016","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00296-019-04422-5","article-title":"Characteristics of patients with giant cell arteritis who experience visual symptoms","volume":"39","author":"Chean","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ejim.2025.06.001_bib0017","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.semarthrit.2019.09.008","article-title":"Characteristics and outcomes of patients with ophthalmologic involvement in giant-cell arteritis: A case-control study","volume":"50","author":"Dumont","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ejim.2025.06.001_bib0018","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01.md.0000119761.27564.c9","article-title":"Risk factors for cranial ischemic complications in giant cell arteritis","volume":"83","author":"Nesher","year":"2004","journal-title":"Medicine"},{"key":"10.1016\/j.ejim.2025.06.001_bib0019","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/ard-2023-223895","volume":"82","author":"Monti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2025.06.001_bib0020","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-019-04339-y","article-title":"Risk of ischaemic events at giant cell arteritis diagnosis according to PET\/CT findings","volume":"46","author":"Mestre-Torres","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejim.2025.06.001_bib0021","article-title":"Visual manifestations in giant cell arteritis: identification of risk factors from the ARTESER Registry","author":"Molina-Collada","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejim.2025.06.001_bib0022","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2025.06.001_bib0023","first-page":"1","article-title":"The treatment of Giant Cell Arteritis in different clinical settings","volume":"9","author":"Pfell","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejim.2025.06.001_bib0024","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.semarthrit.2017.12.009","article-title":"Treatments for giant cell arteritis: Meta-analysis and assessment of estimates reliability using the fragility index","volume":"48","author":"Berti","year":"2018","journal-title":"Seminars Arthritis Rheum"},{"key":"10.1016\/j.ejim.2025.06.001_bib0025","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1136\/ard-2022-223480","article-title":"2002 American College of Rheumatology\/EULAR classification criteria for giant cell arteritis","volume":"81","author":"Ponte","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2025.06.001_bib0026","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/PAS.0000000000000244","article-title":"Inflamed Temporal Artery. Histologic findings in 354 Biopsies, with clinical correlations","volume":"38","author":"Cavazza","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejim.2025.06.001_bib0027","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaut.2016.03.005","article-title":"Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis","volume":"69","author":"Muratore","year":"2016","journal-title":"J Autoimmunity"},{"key":"10.1016\/j.ejim.2025.06.001_bib0028","article-title":"Regresi\u00f3n log\u00edstica binaria, multinomial, de Poisson y binomial negative. Barcelona","volume":"21","author":"Dom\u00e9nech","year":"2023","journal-title":"Graunt"},{"key":"10.1016\/j.ejim.2025.06.001_bib0029","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1007\/s10067-021-05643-5","article-title":"Characterization of visual manifestations and identification of risk factors for permanent vision loss in patients with giant cell arteritis","volume":"40","author":"Baalbaki","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"117","key":"10.1016\/j.ejim.2025.06.001_bib0030","first-page":"S61","article-title":"Ocular ischemic complications in giant cell arteritis: CHADS2-score predicts risk of permanent visual impairment","volume":"37","author":"Czihal1","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ejim.2025.06.001_bib0031","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/rheumatology\/ken480","article-title":"High incidence of severe ischemic complications in patients with giant cell arteritis irrespective of platelet count and size and platelet inhibition","volume":"48","author":"Berger","year":"2009","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.ejim.2025.06.001_bib0032","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12916-017-0871-z","article-title":"Diagnostic delay for giant cell arteritis: a systematic review and meta-analysis","volume":"15","author":"Prior","year":"2017","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.ejim.2025.06.001_bib0033","first-page":"6","article-title":"Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study","volume":"33","author":"Patil","year":"2015","journal-title":"Clin Exp Rheumatol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525002304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525002304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T02:32:34Z","timestamp":1756693954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620525002304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":33,"alternative-id":["S0953620525002304"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.06.001","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of risk factors for permanent visual loss in patients with giant cell arteritis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"106372"}}